Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Vancomycin in Unresectable Fibrolamellar Hepatocellular Carcinoma
NCT04025567Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Mar 2020
- Primary completion
- Dec 2021
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vancomycin in fibrolamellar hepatocellular carcinoma (FLHCC), sponsored by National Cancer Institute. Planned start Mar 2020; status: withdrawn.
02
Drugs
vancomycin
03
Conditions
fibrolamellar hepatocellular carcinoma (FLHCC)
Beyond the preview
Go deeper on NCT04025567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04025567.